FierceBiotech12h
Entrada’s 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...
Entrada Shares Climb After FDA Removes Hold on Muscular Dystrophy Treatment
Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...
Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now
We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...
Managed Healthcare Executive12d
Entrada Therapeutics On Track For New DMD Study in the U.K.
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
FDA批准Entrada杜氏肌营养不良症药物研究
波士顿 - 根据 InvestingPro 数据显示，市值4.76亿美元且财务状况良好的生物科技公司Entrada Therapeutics, Inc. (NASDAQ: TRDA )已获得美国食品和药物管理局（FDA）批准，可以开展其杜氏肌营养不良症（DMD）实验性治疗药物ENTR-601-44的1b期临床试验。此前，英国药品和保健品监管局也批准了相关研究。
Calvin College1y
Entrada Scholars Program
Entrada is a four-week program for students of color in grades 11 and 12. You’ll learn like a university student, live in the dorms, and earn college credit. Entrada students earn $6,000–$10,000 in ...
H.C. Wainwright maintains $20 target on Entrada Therapeutics stock
Entrada Therapeutics (NASDAQ:TRDA) shares maintained a Buy rating and a $20.00 price target from H.C. Wainwright, well below the highest analyst target of $29.00. According to InvestingPro analysis, ...
Entrada Therapeutics推进杜氏肌营养不良症治疗研究
杜氏肌营养不良症是一种罕见疾病，在美国和欧洲影响约41,000人，治疗选择有限。Entrada的EEV治疗平台旨在通过将治疗药物递送到细胞内，接触先前无法到达的细胞内靶点，从而满足这一未满足的医疗需求。
Entrada announces FDA removal of clinical hold on ENTR-601-44
Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...